https://techpapersworld.com/wp-content/uploads/2022/05/Addex-Provides-Update-on-Dipraglurant-Blepharospasm-Phase-2-1280x720.jpg

Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the outcome of a small Phase 2a feasibility study of dipraglurant in patients with blepharospasm was inconclusive and did not meet all of its objectives. Dipraglurant is a metabotropic glutamate receptor subtype 5 negative allosteric modulator, or mGlu5 NAM. “While not showing conclusive effects of dipraglurant in this first study of an mGlu5NAM in blepharospasm...